# Orforglipron China Approval: First GLP-1 Weight Loss Pill

Source: https://www.dietglp.com/blog/orforglipron-china-approval/
Published: 2026-11-12
Keywords: orforglipron china approval, orforglipron approval in china, orforglipron china, orforglipron china application, orforglipron made in china, orforglipron manufacturer in china, orforglipron in chinese, is foundayo available in china, foundayo china, weight loss pill china, new weight loss drug china, weight loss drugs china, eli lilly weight loss pill china, orforglipron nmpa

**TL;DR:** China approved orforglipron, Eli Lilly's once-a-day GLP-1 pill, for weight loss on November 12, 2026. It is the first GLP-1 weight loss pill approved in China, ahead of Novo Nordisk's Wegovy pill. It is the same drug sold as Foundayo in the US, and in China it carries the brand name 穆优达. Lilly has not announced a China price or a launch date yet. The pill lowers appetite, so protein and strength work still matter; [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) gives you one protein target and one 20-minute workout a day.

Is orforglipron approved in China? Yes. On November 12, 2026, China's drug regulator approved orforglipron, Eli Lilly's once-a-day GLP-1 pill, for weight management in adults. That makes Lilly the first company with a GLP-1 weight loss pill approved in China, ahead of Novo Nordisk. It is the same drug Americans know as **Foundayo (orforglipron)**. There is no China price or launch date yet.

Here is what was approved, who qualifies, what is still unknown, and what it means if you already take a GLP-1.

---

## Orforglipron China approval at a glance

| Question | Answer (as of November 12, 2026) |
|---|---|
| What was approved | Orforglipron tablets, a once-daily GLP-1 pill |
| Who approved it | China's National Medical Products Administration (NMPA) |
| Date | November 12, 2026 |
| Brand name in China | 穆优达 (per Chinese media) |
| Approved use | Weight management in adults, with diet control and more exercise |
| Who qualifies | Obesity, or overweight with at least one weight-related condition |
| Type 2 diabetes use | Still under NMPA review |
| Price in China | Not announced |
| Launch date | Not announced |

The news came from Lilly's China unit and was reported by Reuters. Chinese outlets, including Cailian Press and The Paper, say the approval also shows on the NMPA website. They describe the pill as a "Class 1" new drug, which is China's category for innovative new medicines.

## What is orforglipron, and what is it called in China?

Orforglipron is a GLP-1 medicine in pill form. It turns on the same receptor as Ozempic, Wegovy and Zepbound, so you feel full sooner and think about food less. Unlike those drugs, it is not a peptide. It is a small-molecule drug, so it works like a regular pill and does not need to be injected.

In the US and the UK it is sold as Foundayo. In China, media report the brand name as 穆优达 and the generic name as 奥氟格列隆钙片. People searching for "orforglipron in Chinese" are looking for those two names.

Lilly says the pill is taken once a day, at any time, with no food or water rules. That matches the US label. Our [Foundayo (orforglipron) guide](/blog/foundayo-orforglipron-guide/) covers the label in full, including side effects and the boxed warning.

## Who can take orforglipron in China?

The approved use is long-term weight management in adults, on top of diet control and more exercise. Cailian Press, citing the NMPA website, reports two groups:

- Adults with a starting BMI of 30 or higher (obesity)
- Adults with a BMI of 27 to under 30 (overweight) who also have at least one weight-related condition, such as high blood pressure, abnormal blood fats, high blood sugar, obstructive sleep apnea or heart disease

These are the same cutoffs as the US label. The Chinese reports do not list which tablet strengths were approved.

The pill is not yet approved in China for type 2 diabetes. Lilly says that application is still under review. For the diabetes trial results, see [orforglipron for type 2 diabetes](/blog/orforglipron-type-2-diabetes/).

## How well does orforglipron work?

The China approval rests on the same global program as the US approval. Two phase 3 trials did most of the work, and both had sites in China:

- **ATTAIN-1:** 3,127 adults with obesity or overweight and no diabetes, 72 weeks. Sites in the US, Brazil, mainland China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan.
- **ATTAIN-2:** about 1,600 adults with obesity or overweight and type 2 diabetes, 72 weeks.

In ATTAIN-1, people on the top dose lost 11.1% of their body weight on average, compared with 2.1% on placebo. That number comes from the US label. The most common side effects were nausea, constipation, diarrhea and vomiting.

Lilly is also planning a smaller trial only in Chinese adults. ClinicalTrials.gov lists it as NCT07790861, a phase 3 study of 192 people that measures weight change at 48 weeks. On November 12, 2026 it was listed as not yet recruiting, with a planned start in December 2026.

A pill that lowers appetite still means eating less, and eating less can cost you muscle along with fat. That is true in any country. A daily protein target and short strength sessions are the fix. [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) gives you one protein number and one 20-minute workout a day, so the weight you lose is mostly fat.

## How much will orforglipron cost in China, and when does it launch?

Nobody knows yet. Reuters asked Lilly about the China price and timing on November 12, 2026 and did not get an immediate answer.

Here is what has been reported:

- **Sales channels.** Before the approval, Lilly executive Patrik Jonsson told Reuters the company planned to sell the pill through its partners Alibaba and JD Health, and that there were no supply limits for China. He put the launch at "anything from late 2026 to early 2027." None of this has been confirmed since approval.
- **Who pays.** Pharmaphorum reports that weight loss drugs in China are self-funded. Public insurance does not cover them.
- **US price for comparison.** In the US, Lilly lists Foundayo from $149 a month for the lowest dose when you pay yourself. A China price may be very different.

## Is orforglipron made in China?

This is a common search, so here is what is on the record. Earlier in 2026 Lilly said it would invest $3 billion in China over 10 years, including local production of oral medicines. Pharmaphorum reports that expanded plants in Suzhou and Beijing are meant to supply orforglipron to the Chinese market.

That is about pills for patients in China. Lilly has not said that those plants make the Foundayo tablets sold in US pharmacies. Do not buy "orforglipron" from overseas sellers online. Products sold that way are unapproved and unverified.

## Where is orforglipron approved now?

| Place | Status | Brand name |
|---|---|---|
| United States | Approved April 1, 2026 for weight loss | Foundayo |
| United Kingdom | Approved August 2026 | Foundayo |
| European Union | Positive committee opinion October 16, 2026 | Foundayo |
| China | Approved November 12, 2026 for weight management | 穆优达 |

## What about the Wegovy pill and other rivals in China?

Lilly got there first with a weight loss pill, but the market is crowded:

- **Wegovy pill.** Novo Nordisk has filed its weight loss semaglutide pill in China. 21st Century Business Herald reports the filing was made in August 2026 and accepted. Novo's semaglutide pill is already approved in China for type 2 diabetes.
- **Injections.** Lilly's tirzepatide shot and Novo's semaglutide shot have both been sold in China since 2024. Reuters also names shots from Pfizer and the Chinese company Innovent Biologics as competitors. Innovent's shot is covered in our [mazdutide guide](/blog/mazdutide/).

The market is large. China's National Health Commission has said more than 65% of people could be overweight or obese by 2030, up from about 50% in 2020. For how the two pills compare on results and side effects, see [Wegovy pill vs Foundayo](/blog/wegovy-pill-vs-foundayo/). If you are choosing between a tablet and an injection, see [GLP-1 pill vs shot](/blog/glp-1-pill-vs-shot/).

## What does this mean if you are in the US?

Nothing changes for US patients today. The price, the label and the supply of Foundayo in the US are the same as yesterday. The China approval mostly shows where GLP-1 treatment is heading: daily pills, in more countries, for more people.

The basics do not change with the country or the form of the drug. Take it as prescribed. Talk to your prescriber before any change. Eat enough protein, and train your muscles a few times a week. Our guides on [how much protein you need on a GLP-1](/blog/protein-target-on-glp1/) and [resistance training on GLP-1](/blog/resistance-training-on-glp1/) show how to start.

## The bottom line

China approved orforglipron for weight loss on November 12, 2026. It is the first GLP-1 weight loss pill in China and the same drug as Foundayo. Price, launch date and tablet strengths for China are not public yet. We will update this guide when Lilly announces them. Whatever form your GLP-1 takes, [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) helps you keep your muscle with one protein target, one short workout and one Shape Score a day.

## Sources

- [Reuters, China approves Eli Lilly's weight loss pill orforglipron, November 12, 2026](https://www.investing.com/news/stock-market-news/china-approves-eli-lillys-weight-loss-pill-orforglipron-5020481)
- [Reuters via RTE, Eli Lilly first to have GLP-1 pill approved in China, November 12, 2026](https://www.rte.ie/news/business/2026/1112/1598928-eli-lilly-first-drugmaker-to-have-a-glp-1-pill-approved-in-china/)
- [Pharmaphorum, Lilly beats Novo to China with an oral GLP-1 for obesity, November 12, 2026](https://pharmaphorum.com/news/lilly-beats-novo-china-oral-glp-1-obesity)
- [Cailian Press via 21jingji, NMPA approval and BMI criteria, November 12, 2026 (Chinese)](https://www.21jingji.com/article/20261112/herald/6ef5c3c46561a89aa658135f7c07f9e9.html)
- [21st Century Business Herald, Lilly oral GLP-1 approved in China, November 12, 2026 (Chinese)](https://www.21jingji.com/article/20261112/herald/8d6bd96dd06ae00f3c3c8bb58c87a7ab.html)
- [The Paper, Lilly oral weight loss drug approved in China, November 12, 2026 (Chinese)](https://www.thepaper.cn/newsDetail_forward_34458967)
- [ClinicalTrials.gov, NCT07790861: orforglipron in Chinese adults with obesity or overweight](https://clinicaltrials.gov/study/NCT07790861)
- [ClinicalTrials.gov, NCT05869903: ATTAIN-1](https://clinicaltrials.gov/study/NCT05869903)
- [Foundayo (orforglipron) prescribing information, DailyMed](https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=foundayo)


## Frequently asked questions

**Q: Is orforglipron approved in China?**

A: Yes. China's National Medical Products Administration (NMPA) approved orforglipron for adult weight management on November 12, 2026, according to Lilly's China unit, Reuters and Chinese media citing the NMPA website. It is the first oral GLP-1 drug approved in China for weight loss.

**Q: What is orforglipron called in China?**

A: Chinese media report the brand name as 穆优达 and the generic name as 奥氟格列隆钙片 (orforglipron calcium tablets). In the US and the UK the same drug is sold as Foundayo.

**Q: Who can get orforglipron in China?**

A: Adults with obesity, or adults with overweight plus at least one weight-related health problem, along with diet control and more exercise. Cailian Press, citing the NMPA website, reports the cutoffs as a starting BMI of 30 or higher, or 27 to under 30 with a condition such as high blood pressure, abnormal blood fats, high blood sugar, sleep apnea or heart disease.

**Q: How much does orforglipron cost in China?**

A: No China price has been announced. Reuters reported on November 12, 2026 that Lilly did not immediately answer questions about pricing or availability. Pharmaphorum reports that weight loss drugs in China are paid for out of pocket.

**Q: When will orforglipron be available in China?**

A: Lilly has not given a launch date. Before the approval, a Lilly executive told Reuters the China launch could be anywhere from late 2026 to early 2027 and that the pill would be sold through Lilly's partners Alibaba and JD Health. Those plans have not been confirmed since the approval.

**Q: Is orforglipron made in China?**

A: Lilly announced in 2026 that it will invest $3 billion in China over 10 years, including local production of oral medicines. Pharmaphorum reports that expanded plants in Suzhou and Beijing are meant to supply orforglipron to the Chinese market. Lilly has not said those plants make the Foundayo tablets sold in the US.

**Q: Is the Wegovy pill approved in China?**

A: Not yet. Novo Nordisk has applied to sell its weight loss semaglutide pill in China. 21st Century Business Herald reports the application was filed in August 2026 and accepted for review. Novo already sells oral semaglutide in China for type 2 diabetes.

